# BIO ESSENCE CORP. (BIOE) · Edgar & Edgarette company card

> Bio Essence (BIOE) grew revenue 486% in FY2025 to $2 million, operating margin 47.4% against a -3.8% median for pharmaceutical preparations, equity -491% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1723059 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/BIOE) · [JSON](https://www.pops4.com/boards/company/BIOE.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $2M |
| Revenue growth, 1 year | 485.8% |
| Revenue growth per year | 20.9% |
| Operating margin | 47.4% (prior year -141.8%) |
| Net margin | 47.2% |
| Operating cash flow | $2M |
| Capital spending | — |
| Free cash flow | — |
| Cash | — |
| Long-term debt | $57,482 |
| Total assets | $422,474 |
| Total equity | −$2M |
| Equity ÷ assets | -490.7% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -91.59 (distress zone)
- Piotroski F: 9 of 9 (strong)
- Health Harbor boat: Weathered boat · two warning signs · liabilities exceed assets (often from years of share buybacks, not always distress); revenue is hard to predict: its 80% range is ±47%
- Cash Compass: Cash cow later · growing fast, and already turning revenue into cash

## Edgarette's reading

Exposure: revenue $1.9M (FY2025), total debt $57K. Experience: revenue up 485.8% on the year, up 20.9% a year over 4 years; operating margin 47.4%, up from -141.8%. Soundness: equity -490.7% of assets (liabilities exceed assets). Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $4.1M and $11.3M next year (method v4.1: its own 4-year record of growth weighed at 50% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $3.8M to $12.1M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin 47.4% against a -3.8% median; growth 485.8% against 13.7%.

Range logged 2026-10-26, receipt 391efaf3fa8b9d96, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-10-23 ([filing](https://www.sec.gov/Archives/edgar/data/1723059/000121390026112075/0001213900-26-112075-index.htm))

## Recent filings

- 10-Q · filed 2026-11-13 · [filing](https://www.sec.gov/Archives/edgar/data/1723059/000121390026119132/0001213900-26-119132-index.htm)
- 8-K · filed 2026-10-23 · 5.02 Departure or Election of Directors; Appointment of Officers; 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year · [filing](https://www.sec.gov/Archives/edgar/data/1723059/000121390026112075/0001213900-26-112075-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1723059/000121390026090174/0001213900-26-090174-index.htm)
- 10-Q · filed 2026-05-15 · [filing](https://www.sec.gov/Archives/edgar/data/1723059/000121390026057529/0001213900-26-057529-index.htm)
- 8-K · filed 2026-04-24 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1723059/000121390026047207/0001213900-26-047207-index.htm)
- 10-K · filed 2026-03-27 · [filing](https://www.sec.gov/Archives/edgar/data/1723059/000121390026035467/0001213900-26-035467-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001723059.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1723059

## Cite

POPS4, Edgar & Edgarette: BIO ESSENCE CORP. (BIOE) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/BIOE. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

